Analysts Set Expectations for BCAX FY2025 Earnings

Bicara Therapeutics Inc. (NASDAQ:BCAX) – Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Bicara Therapeutics in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst E. Schmidt expects that the company will earn ($2.50) per share for the year. Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Bicara Therapeutics’ current full-year earnings is ($2.59) per share.

Bicara Therapeutics (NASDAQ:BCAX) last issued its earnings results on Tuesday, November 12th. The company reported ($1.60) EPS for the quarter, missing the consensus estimate of ($0.46) by ($1.14).

Several other equities research analysts also recently commented on BCAX. Rodman & Renshaw began coverage on shares of Bicara Therapeutics in a research note on Tuesday, November 5th. They issued a “buy” rating and a $48.00 target price on the stock. Stifel Nicolaus assumed coverage on shares of Bicara Therapeutics in a research note on Tuesday, October 8th. They set a “buy” rating and a $47.00 price objective on the stock. TD Cowen started coverage on shares of Bicara Therapeutics in a research note on Tuesday, October 8th. They issued a “buy” rating for the company. RODMAN&RENSHAW upgraded Bicara Therapeutics to a “strong-buy” rating in a research report on Tuesday, November 5th. Finally, Morgan Stanley started coverage on Bicara Therapeutics in a research report on Tuesday, October 8th. They issued an “overweight” rating and a $35.00 price objective for the company. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $43.00.

Bicara Therapeutics Price Performance

Shares of BCAX opened at $11.73 on Thursday. The business’s 50-day simple moving average is $17.46. Bicara Therapeutics has a 12 month low of $11.51 and a 12 month high of $28.09.

Institutional Investors Weigh In On Bicara Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in BCAX. SG Americas Securities LLC bought a new position in Bicara Therapeutics in the fourth quarter valued at about $147,000. Cinctive Capital Management LP bought a new stake in shares of Bicara Therapeutics during the third quarter worth approximately $229,000. Barclays PLC acquired a new position in Bicara Therapeutics in the third quarter valued at approximately $255,000. Jane Street Group LLC bought a new position in Bicara Therapeutics in the third quarter valued at approximately $309,000. Finally, Teachers Retirement System of The State of Kentucky acquired a new stake in Bicara Therapeutics during the 3rd quarter worth $358,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.